⌕
Oruka Therapeutics · ORKA · Nasdaq
Tenet 54 · Mixed
Compare
$96.32−2.94%At closeTenet 54 · Mixed
$96.32−2.92 (−2.94%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Oruka Therapeutics (ORKA) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is ORKA's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Seeking AlphaNov 17, 2026 · 14:22 ET
Oruka Therapeutics, Inc. (ORKA) Presents at UBS Global Biopharma Conference 2026 Transcript

Oruka Therapeutics, Inc. (ORKA) Presents at UBS Global Biopharma Conference 2026 Transcript…

ORKA −2.9% todayRead at source ↗
● GlobeNewsWireNov 9, 2026 · 16:04 ETCOMPANY'S OWN WORDS
Oruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

EVERLAST-B Week 16 results showed 61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose group, highly consistent with EVERLAST-A…

ORKA −2.9% todayRead at source ↗
● Defense WorldNov 9, 2026 · 04:05 ET
Oruka Therapeutics, Inc. $ORKA Stock: Candriam S.C.A. Lowers Holdings

Candriam S.C.A. trimmed its holdings in Oruka Therapeutics, Inc. (NASDAQ: ORKA) by 3.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional inv…

ORKA −2.9% todayRead at source ↗
● GlobeNewsWireNov 3, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Oruka Therapeutics to Participate in Multiple Upcoming Conferences

MENLO PARK, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment …

ORKA −2.9% todayRead at source ↗
● MarketBeatOct 26, 2026 · 23:02 ET
Oruka's ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study

Oruka Therapeutics NASDAQ: ORKA reported interim week 16 results from EVERLAST-B, a Phase IIb dose-ranging study of ORKA-001 in adults with moderate-to-severe plaque psoriasis. The company said its 600-milligram regimen …

ORKA −2.9% todayRead at source ↗
● Seeking AlphaOct 26, 2026 · 12:49 ET
Oruka Therapeutics, Inc. (ORKA) Discusses Interim EVERLAST-B Results for ORCA 001 in Plaque Psoriasis Transcript

Oruka Therapeutics, Inc. (ORKA) Discusses Interim EVERLAST-B Results for ORCA 001 in Plaque Psoriasis Transcript…

ORKA −2.9% todayRead at source ↗
● BenzingaOct 26, 2026 · 12:45 ET
Oruka Therapeutics Novel Biologic Outperforms Placebo in Psoriasis Trial

Oruka Therapeutics Inc. (NASDAQ:ORKA) on Monday reported positive Week 16 results from its EVERLAST-B Phase 2b clinical trial evaluating ORKA-001 in patients with moderate-to-severe plaque psoriasis.…

ORKA −2.9% todayRead at source ↗
● GlobeNewsWireOct 26, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis

61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-A Continued favorable safety and tolerability profile consistent with the IL-23p19 class ORKA-001 on track to advance into…

ORKA −2.9% todayRead at source ↗
● GlobeNewsWireOct 25, 2026 · 12:00 ETCOMPANY'S OWN WORDS
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026

MENLO PARK, Calif., Oct. 25, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment …

ORKA −2.9% todayRead at source ↗
● Defense WorldOct 19, 2026 · 08:07 ET
Oruka Therapeutics (NASDAQ:ORKA) Stock Keeps “Buy” Rating at BTIG Research

Oruka Therapeutics (NASDAQ: ORKA - Get Free Report)'s stock had its "buy" rating restated by analysts at BTIG Research in a research report issued on Monday, Benzinga reports. They currently have a $151.00 price target o…

ORKA −2.9% todayRead at source ↗
● Seeking AlphaOct 18, 2026 · 06:34 ET
Oruka Therapeutics: The Psoriasis Market Is Becoming A Barbell, And ORKA-001 Owns The Far End

Oruka Therapeutics is positioned as a leader in ultra-long-acting injectable treatments for psoriasis, with ORKA-001 showing class-leading efficacy. ORKA-001's PASI 100 and PASI 90 rates at Week 28 reinforce its durabili…

ORKA −2.9% todayRead at source ↗
● Zacks Investment ResearchSep 24, 2026 · 11:35 ET
ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data

Oruka's ORKA-001 delivers deeper psoriasis clearance at week 28, but safety disclosures may have weighed on shares despite positive efficacy data.…

ORKA −2.9% todayRead at source ↗
● BenzingaSep 23, 2026 · 09:49 ET
Oruka Therapeutics Says Psoriasis Drug Shows Deepening Efficacy

Oruka Therapeutics Inc. (NASDAQ:ORKA) on Wednesday reported positive week 28 outcomes from its Phase 2a clinical trial evaluating ORKA-001 for moderate-to-severe plaque psoriasis.…

ORKA −2.9% todayRead at source ↗
● GlobeNewsWireSep 23, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing

PASI 100 increased to 71.4% and PASI 90 increased to 87.3%, despite no dosing after Week 4 Placebo crossover patients reached PASI 100 and PASI 90 rates similar to those initially dosed with ORKA-001 ORKA-001 maintained …

ORKA −2.9% todayRead at source ↗
● GlobeNewsWireSep 9, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference

MENLO PARK, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment…

ORKA −2.9% todayRead at source ↗
● Zacks Investment ResearchAug 28, 2026 · 12:11 ET
ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know

Oruka's three-month rally reflects investor confidence in ORKA-001, with key clinical data and pipeline milestones scheduled ahead.…

ORKA −2.9% todayRead at source ↗
● Defense WorldAug 25, 2026 · 03:55 ET
BlackRock Inc. Purchases Shares of 4,990,181 Oruka Therapeutics, Inc. $ORKA

BlackRock Inc. purchased a new position in Oruka Therapeutics, Inc. (NASDAQ: ORKA) during a recent quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fu…

ORKA −2.9% todayRead at source ↗
● GlobeNewsWireAug 24, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer

MENLO PARK, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment …

ORKA −2.9% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA31−0.4%
WDAY4−5.8%
EG3−2.0%

Article counts from the last market-wide feed page, across every symbol we track and not just ORKA · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.